Viral Hepatitis Market Report 2026

Viral Hepatitis Market Overview

• Viral Hepatitis market size has reached to $16.77 billion in 2025 • Expected to grow to $20.85 billion in 2030 at a compound annual growth rate (CAGR) of 4.7% • Growth Driver: Elevated Prevalence Of Hepatitis Driving Growth In The Viral Hepatitis Market • Market Trend: Enhancing Screening Accuracy With Next-Generation Immunoassays • North America was the largest region in 2025.

What Is Covered Under Viral Hepatitis Market?

Viral hepatitis refers to a group of infectious diseases caused by different viruses (hepatitis A, B, C, D and E), which primarily affect the liver. The symptoms can vary depending on the specific virus, but common manifestations include fatigue, jaundice, abdominal pain, nausea, vomiting and fever. The main types of viral hepatitis diseases are hepatitis A, hepatitis B, hepatitis C and others. Hepatitis A is a potentially fatal liver illness caused by the hepatitis A virus. The various diagnosis is liver biopsy, blood tests, imaging tests and others with antiviral drugs, surgery, vaccine, immune modulator drugs and others. The various routes of administration are oral, parenteral and others. It is used in hospitals, specialty clinics, homecare and others.

What Is The Viral Hepatitis Market Growth Forecast?

The viral hepatitis market size is expected to see steady growth in the next few years. It will grow to $20.85 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to increasing focus on hepatitis elimination initiatives, rising investments in novel antiviral drugs, expansion of point-of-care diagnostics, growing adoption of combination therapies, increasing global screening programs. Major trends in the forecast period include increasing adoption of advanced antiviral therapies, rising use of molecular diagnostic techniques, growing focus on early disease detection, expansion of vaccination programs, enhanced monitoring of chronic hepatitis cases.

Global Viral Hepatitis Market Segmentation

1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types 2) By Diagnosis: Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnosis 3) By Treatment: Antiviral Drugs, Surgery, Vaccine, Immune Modulator Drugs, Other Treatments 4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsegments: 1) By Hepatitis A: Acute Hepatitis A, Chronic Hepatitis A 2) By Hepatitis B: Acute Hepatitis B, Chronic Hepatitis B, Hepatitis B Carrier 3) By Hepatitis C: Acute Hepatitis C, Chronic Hepatitis C 4) By Other Disease Types: Hepatitis D, Hepatitis E

What Is The Driver Of The Viral Hepatitis Market?

The rising prevalence of hepatitis is expected to propel the growth of the viral hepatitis market going forward. Hepatitis is an infection of the liver caused by several infectious viruses and non-infectious substances, which can result in several medical issues. Hepatitis A, B, C, D and E are among the viruses that can cause viral hepatitis, which results in liver inflammation and damage. For instance, in April 2025, according to the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union (EU) health agency, in 2023, 30 EU/EEA Member States reported 37,766 newly diagnosed cases of hepatitis B virus (HBV) infection, corresponding to a crude rate of 8.1 cases per 100 000 population. Therefore, the rising prevalence of hepatitis will drive the viral hepatitis industry.

Key Players In The Global Viral Hepatitis Market

Major companies operating in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd.

Global Viral Hepatitis Market Trends and Insights

Major companies operating in the viral hepatitis market are focusing on incorporating advanced immunoassay technologies such as automated, dual-marker immunoassays to enhance early detection and disease monitoring. Automated, dual-marker immunoassays are in-vitro diagnostic tests that simultaneously detect both antigen and antibody from a single sample, enabling capabilities such as near-real-time analysis of infection status, shortened diagnostic window, and improved screening throughput. For instance, in July 2023, Roche Diagnostics India, an India-based provider of in-vitro diagnostics and laboratory automation solutions, launched Elecsys HCV Duo, a dual-antigen and antibody immunoassay designed to detect hepatitis C virus, featuring simultaneous independent detection of HCV core antigen and anti-HCV antibodies from a single serum or plasma sample, significantly earlier diagnosis of active HCV infection, and compatibility with automated analyzer platforms such as cobas e 402 and e 801. Elecsys HCV Duo improves early detection, faster linkage to care, streamlined diagnostic workflows, and reduced burden on healthcare systems.

What Are Latest Mergers And Acquisitions In The Viral Hepatitis Market?

In November 2023, GSK plc, a U.K.-based pharmaceuticals company, acquired exclusive rights to hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. With the rights to JNJ-3989 (also known as ARO-HBV), an antisense oligonucleotide drug, GSK aims to expand its portfolio and strengthen its position in the treatment of chronic hepatitis B by adding a new, potentially valuable therapy to its offerings. Janssen Pharmaceuticals, a Belgium-based subsidiary of Johnson & Johnson, specializes in developing treatments for infectious diseases such as chronic hepatitis B.

Regional Outlook

North America was the largest region in the viral hepatitis market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Viral Hepatitis Market?

The viral hepatitis market consists of revenues earned by entities by providing services such as treatment, testing, awareness programs and diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral hepatitis market also includes the sales of treatments such as vaccines and medication. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Viral Hepatitis Market Report 2026?

The viral hepatitis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the viral hepatitis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.